Factor Xa Inhibitor [EPC]
Semantic Scholar uses AI to extract papers important to this topic.
Essentials The value of thrombin generation assay (TGA) in monitoring direct oral anticoagulants (DOAC) is not well defined. TGA… Expand The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the… Expand PurposeWe report on a 72-year-old male patient who developed a nontraumatic spinal subdural hematoma (SSDH) during rivaroxaban… Expand Compared with the coronary setting, knowledge about antithrombotic therapies after endovascular treatment (EVT) is inadequate in… Expand The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE… Expand OBJECTIVES
The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for… Expand Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip… Expand OBJECTIVES
The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among… Expand Major orthopedic surgery is associated with a high risk of venous thromboembolism (VTE). Anticoagulants are recommended to… Expand Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial… Expand